ZANGRILLI, ARIANNA
 Distribuzione geografica
Continente #
NA - Nord America 5.766
AS - Asia 948
EU - Europa 766
SA - Sud America 135
AF - Africa 14
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.639
Nazione #
US - Stati Uniti d'America 5.721
SG - Singapore 395
CN - Cina 221
IT - Italia 137
RU - Federazione Russa 126
BR - Brasile 117
DE - Germania 88
IE - Irlanda 86
HK - Hong Kong 78
VN - Vietnam 73
SE - Svezia 71
FR - Francia 63
GB - Regno Unito 63
UA - Ucraina 53
BD - Bangladesh 43
CA - Canada 32
FI - Finlandia 31
IN - India 30
JP - Giappone 20
KR - Corea 17
UZ - Uzbekistan 15
PL - Polonia 12
MX - Messico 10
AU - Australia 9
KG - Kirghizistan 8
AR - Argentina 7
ES - Italia 7
NL - Olanda 7
RO - Romania 7
ID - Indonesia 6
IQ - Iraq 6
PK - Pakistan 6
TR - Turchia 6
MY - Malesia 5
JO - Giordania 4
ZA - Sudafrica 4
AT - Austria 3
BE - Belgio 3
CL - Cile 3
EC - Ecuador 3
EG - Egitto 3
MA - Marocco 3
PH - Filippine 3
CH - Svizzera 2
CO - Colombia 2
DK - Danimarca 2
IL - Israele 2
KE - Kenya 2
NP - Nepal 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BG - Bulgaria 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EU - Europa 1
GE - Georgia 1
IR - Iran 1
KH - Cambogia 1
LT - Lituania 1
MD - Moldavia 1
NI - Nicaragua 1
OM - Oman 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
Totale 7.639
Città #
Wilmington 1.476
Houston 1.175
Woodbridge 1.101
Singapore 264
Fairfield 222
Chandler 196
Ashburn 185
San Jose 122
Ann Arbor 104
Seattle 89
Cambridge 85
Dublin 81
Beijing 80
Hong Kong 74
New York 64
Medford 61
Council Bluffs 49
Dearborn 45
The Dalles 45
Jacksonville 42
Los Angeles 35
Rome 31
Santa Clara 29
Lawrence 28
Ho Chi Minh City 24
Lauterbourg 23
Tokyo 20
Buffalo 18
Dallas 18
Zhengzhou 18
Helsinki 17
Brooklyn 16
Moscow 16
San Diego 16
Hanoi 15
Milan 13
Montreal 13
Chennai 12
Munich 12
Shanghai 12
Boardman 11
Atlanta 10
Denver 10
São Paulo 10
Warsaw 10
Orem 9
Hefei 8
London 8
Manchester 8
Redondo Beach 8
Seoul 8
Brasília 7
Menlo Park 7
Norwalk 7
Redmond 7
Redwood City 7
Stockholm 7
Toronto 7
Chicago 6
Nuremberg 6
Phoenix 6
Sydney 6
Ankara 5
Belo Horizonte 5
Bologna 5
Esslingen am Neckar 5
Lappeenranta 5
Mexico City 5
Nanjing 5
Rio de Janeiro 5
San Francisco 5
Amman 4
Bari 4
Da Nang 4
Detroit 4
Kilburn 4
Palo Alto 4
Poplar 4
Raleigh 4
Sedico 4
Augusta 3
Baghdad 3
Boston 3
Brussels 3
Charlotte 3
City of London 3
Florence 3
Genazzano 3
Guangzhou 3
Jinan 3
Mülheim 3
Nanchang 3
Paris 3
Pescara 3
Quảng Ngãi 3
Alpharetta 2
Aprilia 2
Biên Hòa 2
Bến Tre 2
Cairo 2
Totale 6.255
Nome #
Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study 482
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 473
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 458
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis 448
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. 422
Erysipeloid cutaneous metastasis from bladder carcinoma 402
TNF-α antagonists and nail psoriasis: An open, 24-week, prospective cohort study in adult patients with psoriasis 396
Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk 395
Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index. 374
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey 352
Radiologically significant joint improvement in a patient affected by psoriatic arthritis treated with adalimumab 315
Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice 273
Paradoxical case effects of psoriasis following adalimumab therapy: A case series 272
Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation 267
One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast 243
Efficacy and safety of Adalimumab in difficult-to-treat psoriasis 203
Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation 198
Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers 197
Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations 178
Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma 145
Omalizumab and adalimumab: a winning couple 141
Adalimumab for moderate to severe psoriasis: an open-label, retrospective 3-year study 141
Ixekizumab: One drug for an enigmatic psoriasis 139
A linear forehead lesion caused by intralesional injection of triamcinolone acetonide and treated with hyaluronic acid filler: case report 131
Paradoxical psoriasis induced by anti-TNFα treatment: evaluation of disease-specific clinical and genetic markers 126
Clinical severity instruments 122
Risankizumab: How to choose the right dose in clinical practice? 113
Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real‐world study 106
Long-term efficacy of adalimumab in generalized pustular psoriasis 100
Effectiveness of ixekizumab in elderly patients for the treatment of moderate-to-severe psoriasis: results from a multicenter, retrospective real-life study in the Lazio region 80
Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: A 52-week Italian real-life experience 72
Improvement of Psoriasis Using Oral Probiotic Streptococcus salivarius K-12: a Case–Control 24-Month Longitudinal Study 67
null 3
Totale 7.834
Categoria #
all - tutte 22.481
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.481


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202123 0 0 0 0 0 0 0 0 0 0 0 23
2021/2022322 15 30 21 25 10 18 17 12 18 50 19 87
2022/2023439 35 51 23 53 36 95 37 22 45 13 15 14
2023/2024148 14 3 8 5 18 29 12 23 4 9 0 23
2024/2025624 27 119 92 27 6 36 66 28 50 62 69 42
2025/20261.442 126 50 146 145 134 57 227 158 107 137 72 83
Totale 7.834